PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model

Since the first clinical trial of the anti-PD-1 agent nivolumab in 2010 [1], PD-1 blockade has revolutionized the field of cancer immunotherapy. Despite the successes of PD-1-blocking agents in cancer treatment, a major and often life-threatening complication of their use is the development of immune-related adverse events (irAEs). The incidence of all irAEs in nivolumab-treated patients ranges from 30% to 45% and more severe grade 3 –4 irAEs occur in 3–7% of patients [2]. Most common are diarrhea/colitis, pruritis, hepatitis, and hypophysitis [3], but a number of relatively rare autoimmune diseases, such as myasthenia gravis [4], autoimmune sarcoidosis [5,6], and autoimmune cytopenias [7–9], have also arisen due to nivolu mab treatment, implying that PD-1 plays an important role in the pathogenesis of these diseases.

Source: Experimental Hematology - March 7, 2018 Category: Hematology Authors: Maile K. Hollinger, Valentina Giudice, Nicole A. Cummings, Guillermo Rivell, Hansheng Zhang, Sachiko Kajigaya, Keyvan Keyvanfar, Jichun Chen, Xingmin Feng, Neal S. Young Source Type: research